Home › Liver Diseases › NCT05264051
MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease
RecruitingObservational study
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Patients who are already scheduled for an MRI for routine clinical purposes will be evaluated Exclusion Criteria: * \<18 yrs. of age
About the study
The purpose of the study is to study the muscle assessment score (MAsS, utilizing MRI, as an objective measure of frailty and muscle composition to serve as a predictor of morbidity and mortality in patients with liver disease.
Sponsor: University of Chicago · Participants: 1,200 · Started: Apr 18, 2022
Contact the study team
- Omar Jamil, MD · Phone: 847-373-2360
- Maria Newsome · Phone: 773-702-2788
Official record on ClinicalTrials.gov — NCT05264051
Locations in the U.S.
| Illinois | The University of Chicago, Chicago |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.